ABSTRACT
Importance A recent study from the U.S. Food and Drug Administration investigated the risk of stroke following COVID-19 bivalent and high-dose/adjuvanted influenza vaccines among older adults (individuals ≥65 years) who experienced stroke after vaccination in the 2022-2023 season. The study found a small but significant association between stroke and high-dose/adjuvanted influenza vaccination in the Medicare fee-for-service (FFS) population.
Objective To evaluate stroke risk following high-dose/adjuvanted influenza vaccines in three historical influenza seasons.
Design, Setting, and Participants The analysis included Medicare beneficiaries ≥65 years who had a stroke outcome after receiving a high-dose or adjuvanted influenza vaccine in three influenza seasons 2016-2019. For each season, the study period began on the first Sunday of August and ended one day before the start of the subsequent season (e.g., Sunday, August 7, 2016 through Saturday, August 5, 2017). A self-controlled case series analysis was performed to compare the risk of stroke in risk intervals (1-21 and 22-42 days) to a control interval (43-90 days).
Exposures High-dose/adjuvanted influenza vaccines.
Main Outcomes and Measures Non-hemorrhagic stroke (NHS), transient ischemic attack (TIA), NHS and/or TIA (NHS/TIA), and hemorrhagic stroke (HS).
Results We observed 29,730 stroke cases in 2016-2017; 34,518 cases in 2017-2018; and 36,869 cases in 2018-2019. In 2016-2017, the primary analysis found a statistically significant association for HS during the 22-42 day risk window (incidence rate ratio (IRR)=1.14, 95% confidence interval (CI) 1.02–1.28; Risk Difference (RD)/100,000 doses=0.84, 95% CI 0.14−1.54) compared to the control interval. However, no significant primary analysis results were identified in 2017-2018 or 2018-2019.
Conclusions and Relevance We did not observe clear, consistent evidence of increased stroke risk following high-dose or adjuvanted influenza vaccination across the three seasons 2016-2019. The statistically significant associations we identified were not consistently observed across outcomes, risk windows, age subgroups, or seasons. The clinical significance of any potential risk of stroke following vaccination must be carefully considered together with the significant benefits of receiving an influenza vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Food and Drug Administration (FDA) as part of the SafeRx Project, a joint initiative of the Centers for Medicare & Medicaid Services and FDA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study did not require full FDA IRB committee review and approval because it was determined to be exempt from the requirements of 45 CFR Part 46; 46.104(d)(2) under the 2018 Common Rule. The use of Medicare administrative data was approved by CMS privacy board under a data use agreement. The analyses utilized only existing records and the subjects cannot be identified. Patient consent was not required since our study was based on CMS claims data and thus does not include factors necessitating patient consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Corrected the abstract line "who experienced stroke after vaccination in the 2023-2024 season" to "who experienced stroke after vaccination in the 2022-2023 season." Corrected the CI of the IRR for the NHS 85+ subgroup analysis results in main body from IRR=1.17, 95% CI 1.06−1.30 to IRR=1.17, 95+ CI 1.06−1.29. Added an additional significant figure to the RD for the 85+ age subgroup for NHS.
Data Availability
Data produced in the present work are contained in the report. Access to original datasets is not available to protect patient information.